Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 1

Conditions

Prostatic Neoplasms 2Glioblastoma 2Choriocarcinoma 2Urinary Bladder Neoplasms 1Ureteral Neoplasms 1Trophoblastic Tumor, Placental Site 1Ovarian Neoplasms 1Liver Neoplasms 1Glioma 1Gestational Trophoblastic Disease 1Fallopian Tube Neoplasms 1Disease Progression 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1Carcinoma, Hepatocellular 1

Interventions

carotuximab 2Bevacizumab 2pegylated granulocyte colony-stimulating factor 1pegfilgrastim 1Thiotepa 1Specimen Handling 1Second-Look Surgery 1Reoperation 1Radiotherapy 1Radiation 1Peripheral Blood Stem Cell Transplantation 1Pemetrexed 1Mesna 1Magnetic Resonance Spectroscopy 1Ifosfamide 1Granulocyte Colony-Stimulating Factor 1Filgrastim 1Etoposide 1Drug Therapy 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Choriocarcinoma × carotuximab × Clear all
NCT02664961 2019-07-23

Study of TRC105 and Bevacizumab in Patients With Refractory Gestational Trophoblastic Neoplasia (GTN)

Tracon Pharmaceuticals Inc.

Phase 2 Terminated
3 enrolled 11 charts
Gynecologic

Choriocarcinoma, Trophoblastic Tumor, Placental Site, Gestational Trophoblastic Disease

NCT02396511 2019-06-11

TRC105 Combined With Standard-dose Bevacizumab for Two Patients With Metastatic And Refractory Choriocarcinoma

Tracon Pharmaceuticals Inc.

Phase 2 Completed
2 enrolled 10 charts

Choriocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡